等級
technical grade
化驗
90%
mp
89-91 °C (lit.)
SMILES 字串
CCNC(=O)\C=C\c1cccc(Br)c1
InChI
1S/C11H12BrNO/c1-2-13-11(14)7-6-9-4-3-5-10(12)8-9/h3-8H,2H2,1H3,(H,13,14)/b7-6+
InChI 密鑰
LDCXGZCEMNMWIL-VOTSOKGWSA-N
尋找類似的產品？ 前往 產品比較指南
P Chiu et al.
Neuropharmacology, 21(3), 273-276 (1982-03-01)
Cinromide, an experimental anticonvulsant (Burroughs Wellcome Co.) was tested against focal cortical (simple partial analog), focal amygdala (complex partial analog), and generalized convulsive (tonic-clonic analog) seizures in the "kindled" rat. The toxicity in the CNS was measured by the ataxia
J S Lockard et al.
Epilepsia, 21(2), 177-182 (1980-04-01)
In a previous study (Lockard et al., 1979) Cinromide (3 bromo-N-ethylcinnamamide), an experimental anticonvulsant (Burroughs-Wellcome Pharmaceutical Co.), was given a preliminary evaluation. Since that research was concerned primarily with EEG paroxysms, the present study was conducted to address drug efficacy
A J Wilensky et al.
European journal of clinical pharmacology, 21(2), 149-153 (1981-01-01)
Cinromide is an experimental anticonvulsant currently in phase II testing. A single oral dose (900 mg) of cinromide was administered to 8 epileptic subjects on phenytoin therapy. Plasma samples drawn during the next 36 h were analyzed for cinromide and
Epilepsia, 30(4), 422-429 (1989-07-01)
This study evaluated the effects of cinromide in patients with Lennox-Gastaut Syndrome. No difference between cinromide and placebo was shown in terms of seizure reduction or global evaluations. This study is important, however, because it represents an effort to overcome
E A Lane et al.
Journal of pharmacokinetics and biopharmaceutics, 13(4), 373-386 (1985-08-01)
A previous study of the metabolic fate of cinromide (3-bromo-N-ethylcinnamamide) in rhesus monkey established that half of a dose is metabolized by N-deethylation to an active metabolite, 3-bromocinnamamide. Both cinromide and its proximal metabolite can be metabolized by amide hydrolysis
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務